Extended Low-Dose Apixaban and Superficial Vein Thrombosis

This post hoc analysis of the Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous ThromboembolismHI-PRO) randomized clinical trial investigates the impact of extended low-dose apixaban on symptomatic superficial vein thrombosis events in patients with provoked venous thromboembolism and enduring risk factors.

Corresponding Author: Gregory Piazza, MD, MS, Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115 (gpiazza@bwh.harvard.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.